Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000556
First received: October 27, 1999
Last updated: December 1, 2005
Last verified: November 2005
  Purpose

To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.


Condition Intervention Phase
Arrhythmia
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Drug: amiodarone
Drug: sotalol
Drug: propafenone
Drug: flecainide
Drug: quinidine
Drug: moricizine
Drug: disopyramide
Drug: procainamide
Drug: adrenergic beta antagonists
Drug: verapamil
Drug: diltiazem
Drug: digoxin
Procedure: catheter ablation
Device: pacemaker, artificial
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: March 1995
Estimated Study Completion Date: September 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Elderly men and women with atrial fibrillation and other risk factors for stroke.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000556

Sponsors and Collaborators
Investigators
Investigator: H. Greene Statistics and Epidemiology Research Corporation (S.E.R.C.)
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000556     History of Changes
Other Study ID Numbers: 100
Study First Received: October 27, 1999
Last Updated: December 1, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Arrhythmias, Cardiac
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Adrenergic Agents
Sotalol
Quinidine
Adrenergic beta-Antagonists
Amiodarone
Propafenone
Verapamil
Digoxin
Disopyramide
Flecainide
Procainamide
Moricizine
Diltiazem
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Adrenergic Antagonists
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Enzyme Inhibitors
Vasodilator Agents
Calcium Channel Blockers
Membrane Transport Modulators

ClinicalTrials.gov processed this record on April 22, 2014